British drugmaker AstraZeneca () said Monday that a Phase 3 trial of a developmental drug failed to achieve "statistical significance" in improving the length of time patients with certain types of breast cancer lived.

The disappointing result for datopotamab deruxtecan (Dato-DXd) is the second for AstraZeneca this month. Another Phase 3 trial 澳洲幸运5官方开奖结果体彩网:failed to improve o♈n the current standard ofꦆ care for lung cancer patients.

AstraZeneca's American depositary receipts (ADRs) fell more than 𒊎1% in recent trading Monday. The stock is up in 2024, though off August highs.

Dato-DXd Has Uncertain Regulatory Future

The drug, being jointly developed with Japanese drugmaker Daiichi Sankyo, has 澳洲幸运5官方开奖结果体彩网:produced positive results in earlier tr♏ials. AstraZeneca said Monday that it planned to submit the new data to regulatory agencies. Analysts said the new data makes approval "less likely," Bloomberg reported.

AstraZeneca executive vice president of oncology research and development Susan Galbraith said the breast cancer treatment landscape has "advanced remarkably" in recent years, and said the new trial and past positive results show the "evidence of the clinical value" of the drug.

The trial included over 700 🀅patients with inoperable or metastatic breast cancer.